These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 9482467)

  • 21. Should the patent system for new medicines be abolished?
    DiMasi JA; Grabowski HG
    Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100
    [No Abstract]   [Full Text] [Related]  

  • 22. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
    Wang Z
    Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmaceuticals and medical devices: business practices. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-36. PubMed ID: 23297448
    [No Abstract]   [Full Text] [Related]  

  • 24. Assessing supplement safety--the FDA's controversial proposal.
    Cohen PA
    N Engl J Med; 2012 Feb; 366(5):389-91. PubMed ID: 22276780
    [No Abstract]   [Full Text] [Related]  

  • 25. UK science and health outside the EU.
    Gulland A
    BMJ; 2016 Jun; 353():i3595. PubMed ID: 27358270
    [No Abstract]   [Full Text] [Related]  

  • 26. [Dosing regimens in second medical use patents].
    Suganuma CA
    Cad Saude Publica; 2017 Sep; 33(9):e00096716. PubMed ID: 28977273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Korea: the new first battleground for the high stakes poker game of pharmaceutical patent litigation.
    Choe JY; Yoon KA; Lee S
    Pharm Pat Anal; 2015; 4(6):409-13. PubMed ID: 26580988
    [No Abstract]   [Full Text] [Related]  

  • 28. Limiting "evergreening" for a better balance of drug innovation incentives.
    Stanbrook MB
    CMAJ; 2013 Aug; 185(11):939. PubMed ID: 23877665
    [No Abstract]   [Full Text] [Related]  

  • 29. Revitalizing the patent system to incentivize pharmaceutical innovation: the potential of claims with means-plus-function clauses.
    Tang WL
    Duke Law J; 2013 Feb; 62(5):1069-108. PubMed ID: 25330553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Realizing two-tiered innovation policy through drug regulation.
    Ridgway WE
    Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmaceutical pricing conundrum: time to get rid of it?
    Garattini L; Padula A
    Eur J Health Econ; 2018 Nov; 19(8):1035-1038. PubMed ID: 30030646
    [No Abstract]   [Full Text] [Related]  

  • 32. Patent protection for medical technologies.
    Brewer C
    Lancet; 1998 May; 351(9115):1591-2. PubMed ID: 10326579
    [No Abstract]   [Full Text] [Related]  

  • 33. Pediatric Exclusivity and Regulatory Authority: Implications of Amgen v HHS.
    Kim J; Ross JS; Kapczynski A
    JAMA; 2018 Jan; 319(1):21-22. PubMed ID: 29117365
    [No Abstract]   [Full Text] [Related]  

  • 34. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
    Gitter DM
    Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
    [No Abstract]   [Full Text] [Related]  

  • 35. Amendments to the Canadian Patent Act to address drug access: is help on the way?
    Penner MD; Narayanan P
    Food Drug Law J; 2005; 60(3):459-70. PubMed ID: 16304751
    [No Abstract]   [Full Text] [Related]  

  • 36. Patents for second medical indications and their potential impact on pharmacare in Canada.
    Scassa T
    Health Law J; 2001; 9():23-59. PubMed ID: 12141223
    [No Abstract]   [Full Text] [Related]  

  • 37. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
    Fernandez DS; Huie JT
    Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug review "behind the curtain": a response to Professor Struve.
    O'Reilly JT
    Cornell Law Rev; 2008 Jul; 93(5):1075-90. PubMed ID: 18618971
    [No Abstract]   [Full Text] [Related]  

  • 39. Patent protection in Europe of pharmaceuticals found to have a further medical indication.
    Cockbain J
    Pharm Pat Anal; 2012 Mar; 1(1):17-8. PubMed ID: 24236708
    [No Abstract]   [Full Text] [Related]  

  • 40. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.